Drug Profile


Alternative Names: HuABC2

Latest Information Update: 30 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JN Biosciences
  • Class Antibodies; Immunotherapies
  • Mechanism of Action Interleukin 2 receptor beta subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Immunological disorders

Most Recent Events

  • 23 May 2017 HuABC 2 is available for licensing as of 23 May 2017. (JN Biosciences pipeline, May 2017)
  • 23 May 2017 Preclinical trials in Immunological disorders in USA (Parenteral) before May 2017 (JN Biosciences pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top